News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|April 9, 2026

Long-Term Toxicity Management in EGFR-Mutated NSCLC

Author(s)Alexander Spira, MD, PhD, FACP, FASCO, Ticiana Leal, MD, Natalie Vokes, MD

Fact checked by: Justin Mancini

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss strategies for monitoring and managing treatment-related adverse events over time in patients receiving adjuvant therapy for early-stage EGFR-mutated non–small cell lung cancer (NSCLC).

Episodes in this series

EP. 1 Evolving Adjuvant Therapy in Early-Stage EGFR-Mutated NSCLC: Insights From ADAURA

EP. 1 Evolving Adjuvant Therapy in Early-Stage EGFR-Mutated NSCLC: Insights From ADAURA

EP. 2 Neoadjuvant Strategies and Early Biomarker Testing in EGFR-Mutated NSCLC

EP. 2 Neoadjuvant Strategies and Early Biomarker Testing in EGFR-Mutated NSCLC

EP. 3 EGFR Biology and Treatment Selection Beyond PD-L1 in EGFR-Mutated NSCLC

EP. 3 EGFR Biology and Treatment Selection Beyond PD-L1 in EGFR-Mutated NSCLC

EP. 4 Osimertinib Across Stages: Shaping Early-Stage EGFR-Mutated NSCLC Care

EP. 4 Osimertinib Across Stages: Shaping Early-Stage EGFR-Mutated NSCLC Care

EP. 5 Interpreting EGFR-TKI Evidence for Early-Stage EGFR-Mutated NSCLC

EP. 5 Interpreting EGFR-TKI Evidence for Early-Stage EGFR-Mutated NSCLC

EP. 6 Real-World Outcomes With EGFR-TKIs in Early-Stage EGFR-Mutated NSCLC

EP. 6 Real-World Outcomes With EGFR-TKIs in Early-Stage EGFR-Mutated NSCLC

EP. 7 Biomarker Testing at Diagnosis in Early-Stage EGFR-Mutated NSCLC

EP. 7 Biomarker Testing at Diagnosis in Early-Stage EGFR-Mutated NSCLC

EP. 8 Multidisciplinary Coordination in EGFR-Mutated NSCLC Treatment Planning

EP. 8 Multidisciplinary Coordination in EGFR-Mutated NSCLC Treatment Planning

EP. 9 Neoadjuvant Decision-Making in EGFR-Mutated NSCLC

EP. 9 Neoadjuvant Decision-Making in EGFR-Mutated NSCLC

EP. 10 Setting Expectations for Long-Term Therapy in EGFR-Mutated NSCLC

EP. 10 Setting Expectations for Long-Term Therapy in EGFR-Mutated NSCLC

EP. 11 Managing EGFR-TKI Toxicities in Early-Stage EGFR-Mutated NSCLC

EP. 11 Managing EGFR-TKI Toxicities in Early-Stage EGFR-Mutated NSCLC

EP. 12 Driving Guideline-Aligned Care in EGFR-Mutated NSCLC

EP. 12 Driving Guideline-Aligned Care in EGFR-Mutated NSCLC

EP. 13 Shared Decision-Making in Early-Stage EGFR-Mutated NSCLC

EP. 13 Shared Decision-Making in Early-Stage EGFR-Mutated NSCLC

EP. 14 Patient Selection for Adjuvant Therapy in EGFR-Mutated NSCLC

EP. 14 Patient Selection for Adjuvant Therapy in EGFR-Mutated NSCLC

EP. 15 Motivating Treatment Persistence in EGFR-Mutated NSCLC

EP. 15 Motivating Treatment Persistence in EGFR-Mutated NSCLC

EP. 16 Long-Term Toxicity Management in EGFR-Mutated NSCLC

EP. 16 Long-Term Toxicity Management in EGFR-Mutated NSCLC

EP. 17 Counseling Persistence in EGFR-Mutated NSCLC Therapy

EP. 17 Counseling Persistence in EGFR-Mutated NSCLC Therapy

EP. 18 Biopsy-Driven Neoadjuvant Planning in EGFR-Mutated NSCLC

EP. 18 Biopsy-Driven Neoadjuvant Planning in EGFR-Mutated NSCLC

EP. 19 Defining Meaningful Outcomes in Neoadjuvant EGFR-Mutated NSCLC

EP. 19 Defining Meaningful Outcomes in Neoadjuvant EGFR-Mutated NSCLC

EP. 20 Surgical Considerations After Neoadjuvant Therapy in EGFR-Mutated NSCLC

EP. 20 Surgical Considerations After Neoadjuvant Therapy in EGFR-Mutated NSCLC

EP. 21 Transitioning to Adjuvant Therapy in EGFR-Mutated NSCLC

EP. 21 Transitioning to Adjuvant Therapy in EGFR-Mutated NSCLC

EP. 22 The Role of Early Biomarker Testing in EGFR-Mutated NSCLC

EP. 22 The Role of Early Biomarker Testing in EGFR-Mutated NSCLC

In this segment, Dr. Alexander Spira and Dr. Ticiana Leal discuss strategies for monitoring and managing treatment-related adverse events over time in patients receiving adjuvant therapy for early-stage EGFR-mutated non–small cell lung cancer (NSCLC). Dr. Leal emphasizes the importance of proactive and continuous monitoring, particularly for common toxicities such as dermatologic reactions and gastrointestinal side effects. The discussion highlights the value of early intervention, patient education, and routine follow-up to identify and address adverse events before they impact adherence. Dr. Leal also notes that appropriate dose modifications, when necessary, can help maintain patients on therapy without compromising tolerability. The conversation reinforces the importance of maintaining open communication with patients to ensure that side effects are reported and managed promptly. This segment underscores how effective long-term toxicity management supports adherence and helps patients complete the intended course of therapy in EGFR-mutated NSCLC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

The Role of Early Biomarker Testing in EGFR-Mutated NSCLC

ByAlexander Spira, MD, PhD, FACP, FASCO,Ticiana Leal, MD,Natalie Vokes, MD ,Edward S. Kim, MD, MBA

April 9th 2026

Transitioning to Adjuvant Therapy in EGFR-Mutated NSCLC

ByAlexander Spira, MD, PhD, FACP, FASCO,Ticiana Leal, MD,Natalie Vokes, MD ,Edward S. Kim, MD, MBA

April 9th 2026

Surgical Considerations After Neoadjuvant Therapy in EGFR-Mutated NSCLC

ByAlexander Spira, MD, PhD, FACP, FASCO,Ticiana Leal, MD,Natalie Vokes, MD ,Edward S. Kim, MD, MBA

April 9th 2026

Defining Meaningful Outcomes in Neoadjuvant EGFR-Mutated NSCLC

ByAlexander Spira, MD, PhD, FACP, FASCO,Ticiana Leal, MD,Natalie Vokes, MD ,Edward S. Kim, MD, MBA

April 9th 2026

Biopsy-Driven Neoadjuvant Planning in EGFR-Mutated NSCLC

ByAlexander Spira, MD, PhD, FACP, FASCO,Ticiana Leal, MD,Natalie Vokes, MD ,Edward S. Kim, MD, MBA

April 9th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

11th Annual School of Gastrointestinal Oncology® (SOGO®)

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Addressing Unmet Needs in HER2+ Metastatic BTC

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Proactive Adverse Event Management for HER2+ BTC Treatments

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Cross-Disease Integration of Immunotherapy Innovations

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Trending on CancerNetwork

FDA Gives Fast Track Status to SIM0505 in Platinum-Resistant Ovarian Cancer

Personalized Cancer Vaccines Show Promise for Select Melanoma Populations

When to Opt for Focal vs Radical Interventions in Localized Prostate Cancer

FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer

Gotistobart Improves Survival vs Docetaxel in Metastatic NSCLC Trial